Interferon News and Research

RSS

Study provides comprehensive update on ACE2 enzyme with key role in SARS-CoV-2 infection

Researchers at Uppsala University have described the presence, throughout the human body, of the enzyme ACE2.

5 Aug 2020

Yale researchers develop new mouse model to study SARS-CoV-2 infection

Researchers at Yale University School of Medicine have developed a new mouse model to study SARS-CoV-2 infection and disease and to accelerate testing of novel treatments and vaccines against the novel coronavirus.

4 Aug 2020

Novel short ACE2 isoform may influence SARS-CoV-2 susceptibility

A study led by researchers at the University of Southampton, UK, has identified a novel short isoform of the full-length receptor that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses to gain entry to host cells.

3 Aug 2020

New bivalent vaccine delivers robust cell-mediated and humoral immunity against SARS-CoV-2

In a groundbreaking bioRxiv study, US researchers demonstrate the capability of next-generation bivalent human adenovirus serotype 5 (hAd5) vaccine for inducing both cellular and humoral immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – using both an S protein sequence optimized for cell surface expression and a conserved nucleocapsid antigen designed to be transported to the endosomal subcellular compartment.

2 Aug 2020

Smoking worsens COVID-19 severity, warn researchers

A study conducted by researchers at the University of California, Los Angeles, suggests that smoking increases the risk of more severe lung disease in cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

30 Jul 2020

Antimalarial drug shows in vitro activity against SARS-CoV-2 and flu viruses

Now, a new study published in the preprint server bioRxiv in July 2020 reports on the antiviral activity of two drugs found in an antimalarial drug currently in phase II trials in South Korea, called Pyramax.

30 Jul 2020

Researchers identify potential anti-viral strategy for SARS-CoV-2 virus

In the case of an infection, the SARS-CoV-2 virus must overcome various defense mechanisms of the human body, including its non-specific or innate immune defense. During this process, infected body cells release messenger substances known as type 1 interferons. These attract natural killer cells, which kill the infected cells.

29 Jul 2020

Varying immune system responses can predict severe COVID-19 outcomes

The differing immune system responses of patients with COVID-19 can help predict who will experience moderate and severe consequences of disease, according to a new study by Yale researchers published July 27 in the journal Nature.

27 Jul 2020

Study reveals manifold applications of cytokine transcriptional response modules in COVID-19

In a recent bioRxiv* study, UK researchers used interleukin modules to investigate the pathology of coronavirus disease (COVID-19).

27 Jul 2020

Researchers identify TLR7 gene that predisposes elderly patients to severe COVID-19

Current observations suggest that the coronavirus SARS-CoV-2 causes severe symptoms mainly in elderly patients with chronic disease.

25 Jul 2020

Non-invasive algorithm predicts complications in patients following recovery from hepatitis C

The chronic viral inflammation of the liver that occurs in hepatitis C results in the formation of inflexible scar tissue in the form of fibrosis/cirrhosis of the liver. This impedes the flow of blood through the organ, with resulting hypertension in the portal vein.

23 Jul 2020

Prednisone, Hydroxychloroquine best among COVID-19 treatments, claims large Spanish study

The COVID-19 pandemic has taken the lives of several hundred thousand people across the world. In Spain, a intense outbreak took a toll of over 28,000 lives.

23 Jul 2020

Study shows interferons do not induce the expression of SARS-CoV-2 cell entry receptor

In a new bioRxiv study, authors identified a isoform of ACE2 (designated as deltaACE2 or dACE2) receptor, shown to be induced in various human cell types.

23 Jul 2020

Mysterious enzyme inhibits inflammation in blood vessels, LJI study shows

Scrape your knee, and you'll see some red puffiness appear around the injury. This is inflammation, and it is driven by the immune system.

23 Jul 2020

Vitamin D could help suppress excessive T cell-mediated lung inflammation in severe COVID-19

As COVID-19 continues to spread over the world scientists continue to seek the reasons for the difference in disease severity from person to person.

22 Jul 2020

Pfizer/BioNTech COVID-19 vaccine elicits both neutralizing antibodies and T cell response

A new study published on the preprint server medRxiv by a research group from the U.S. and Germany indicates that a novel BNT162b1 RNA-based vaccine against coronavirus disease (COVID-19) induces functional and proinflammatory T cell responses in almost all participants – marking another landmark achievement for this promising vaccine candidate.

21 Jul 2020

A multi-omics single cell analysis on COVID-19

Now, a new study published on the preprint server medRxiv aims to analyze the immune response over time, using multi-omics in the study of a single cell.

21 Jul 2020

Type 1 interferon deficiency as a biomarker for detecting patients at risk of severe COVID-19

Approximately 5% of people with Covid-19 progress to a severe or critical form, including the development of severe pneumonia that progresses to acute respiratory distress syndrome.

17 Jul 2020

Study shows fused lung cells are pervasive in severe COVID-19

In a recent bioRxiv paper, scientists from Institut Pasteur and other research centers in France demonstrated how pathological effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are modulated by cellular proteins that can either inhibit or facilitate cell fusion and subsequent syncytia formation.

16 Jul 2020

CBD may help reduce cytokine storm and excessive lung inflammation in COVID-19

Cannabidiol, or CBD, may help reduce the cytokine storm and excessive lung inflammation that is killing many patients with COVID-19, researchers say.

16 Jul 2020

Interferon News and Research

Study provides comprehensive update on ACE2 enzyme with key role in SARS-CoV-2 infection

Yale researchers develop new mouse model to study SARS-CoV-2 infection

Novel short ACE2 isoform may influence SARS-CoV-2 susceptibility

New bivalent vaccine delivers robust cell-mediated and humoral immunity against SARS-CoV-2

Smoking worsens COVID-19 severity, warn researchers

Antimalarial drug shows in vitro activity against SARS-CoV-2 and flu viruses

Researchers identify potential anti-viral strategy for SARS-CoV-2 virus

Varying immune system responses can predict severe COVID-19 outcomes

Study reveals manifold applications of cytokine transcriptional response modules in COVID-19

Researchers identify TLR7 gene that predisposes elderly patients to severe COVID-19

Non-invasive algorithm predicts complications in patients following recovery from hepatitis C

Prednisone, Hydroxychloroquine best among COVID-19 treatments, claims large Spanish study

Study shows interferons do not induce the expression of SARS-CoV-2 cell entry receptor

Mysterious enzyme inhibits inflammation in blood vessels, LJI study shows

Vitamin D could help suppress excessive T cell-mediated lung inflammation in severe COVID-19

Pfizer/BioNTech COVID-19 vaccine elicits both neutralizing antibodies and T cell response

A multi-omics single cell analysis on COVID-19

Type 1 interferon deficiency as a biomarker for detecting patients at risk of severe COVID-19

Study shows fused lung cells are pervasive in severe COVID-19

CBD may help reduce cytokine storm and excessive lung inflammation in COVID-19

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News